Show simple item record

dc.contributor.authorTagaya, Y.
dc.contributor.authorMatsuoka, M.
dc.contributor.authorGallo, R.
dc.date.accessioned2019-03-29T14:19:01Z
dc.date.available2019-03-29T14:19:01Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062713996&doi=10.12688%2ff1000research.17479.1&partnerID=40&md5=6d1d5d28f5812b66cf35359c62373d96
dc.identifier.urihttp://hdl.handle.net/10713/8552
dc.description.abstractIt has been nearly 40 years since human T-cell leukemia virus-1 (HTLV-1), the first oncogenic retrovirus in humans and the first demonstrable cause of cancer by an infectious agent, was discovered. Studies indicate that HTLV-1 is arguably one of the most carcinogenic agents to humans. In addition, HTLV-1 causes a diverse array of diseases, including myelopathy and immunodeficiency, which cause morbidity and mortality to many people in the world, including the indigenous population in Australia, a fact that was emphasized only recently. HTLV-1 can be transmitted by infected lymphocytes, from mother to child via breast feeding, by sex, by blood transfusion, and by organ transplant. Therefore, the prevention of HTLV-1 infection is possible but such action has been taken in only a limited part of the world. However, until now it has not been listed by the World Health Organization as a sexually transmitted organism nor, oddly, recognized as an oncogenic virus by the recent list of the National Cancer Institute/National Institutes of Health. Such underestimation of HTLV-1 by health agencies has led to a remarkable lack of funding supporting research and development of treatments and vaccines, causing HTLV-1 to remain a global threat. Nonetheless, there are emerging novel therapeutic and prevention strategies which will help people who have diseases caused by HTLV-1. In this review, we present a brief historic overview of the key events in HTLV-1 research, including its pivotal role in generating ideas of a retrovirus cause of AIDS and in several essential technologies applicable to the discovery of HIV and the unraveling of its genes and their function. This is followed by the status of HTLV-1 research and the preventive and therapeutic developments of today. We also discuss pending issues and remaining challenges to enable the eradication of HTLV-1 in the future.en_US
dc.description.urihttps://dx.doi.org/10.12688/f1000research.17479.1en_US
dc.language.isoen_USen_US
dc.publisherF1000 Research Ltd.en_US
dc.relation.ispartofF1000Research
dc.subjectadult T-cell leukemiaen_US
dc.subjectCentral Australiaen_US
dc.subjectHAM/TSPen_US
dc.subjecthuman oncovirusen_US
dc.subjecthuman retrovirusen_US
dc.subjectHuman T-cell leukemia virus-1en_US
dc.subjectSTDen_US
dc.subjectvaccineen_US
dc.title40 years of the human T-cell leukemia virus: past, present, and futureen_US
dc.typeReviewen_US
dc.identifier.doi10.12688/f1000research.17479.1
dc.identifier.pmid30854194


This item appears in the following Collection(s)

Show simple item record